Protocol Ledger

NCT05785624 · Phase II · TERMINATED

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Interventional Phase II clinical trial protocol NCT05785624 sponsored by Roche / Genentech in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-26 Enrollment: 286 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05785624
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)286 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05785624
Protocol FieldVerified Registry Value
NCT IdentifierNCT05785624
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment286 participants (ACTUAL)
Registered Start Date2023-05-26
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI